Market Place
Sourcing Support
Zentalis Reports Azenosertib Activity In Cyclin E1+ Ovarian Cancer
29 Jan 2025 //
GLOBENEWSWIRE
Zentalis Pharmaceuticals Restructures To Support Azenosertib
28 Jan 2025 //
GLOBENEWSWIRE
Zentalis Gains Fast Track for Azenosertib & Hosts Corporate Event
09 Jan 2025 //
GLOBENEWSWIRE
Zentalis Pharma to Present Preclinical Azenosertib Data at ESMO 2024
09 Sep 2024 //
GLOBENEWSWIRE
Zentalis Hit With FDA Partial Clinical Hold on Cancer Studies,Patient Deaths
19 Jun 2024 //
BIOSPACE
Zentalis Pharmaceuticals Q1 2024 Results And Operational Progress
07 May 2024 //
GLOBENEWSWIRE
Zentalis to Highlight Preclinical Data Demonstrating Azenosertib at AACR
02 Apr 2024 //
GLOBENEWSWIRE
Zentalis Announces Azenosertib Dosing Doubles Efficacy Over Continuous Dosing
06 Jun 2023 //
GLOBENEWSWIRE
Zentalis Announces Presentation of Phase 1b Data Demonstrating Azenosertib
25 May 2023 //
GLOBENEWSWIRE
Zentalis to present +VE clinical data in ovarian cancer combining azenosertib
26 Apr 2023 //
GLOBENEWSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.